Israeli biotech company successfully grows bones in lab

Haifa-based biotech company Bonus BioGroup has entered the second trial of a clinical study seeking to regrow bones in a lab. The first trial, which began four years ago and comprised 32 patients, was completed successfully, according to Dr. Shai Meretzki, CEO and founder of Bonus BioGroup.

The process they have designed could come out of an an H.G. Wells novel. Liposuction is used to retrieve fat cells from the body, from which damage-controlling cells are isolated. The isolated cells are then grown in a bioreactor, a man-made simulation of the human body. After two weeks, the new bone, tailored to the patient’s needs, is injected back inside of the patient in the form of thousands of tiny, living bone particles called BonoFill.

According to Meretzki, the new bone is very much alive. It can be strengthened, and it can grow along with the patient, a particular point of interest when it comes to regenerating children’s bones. Elderly patients, as well as patients suffering from osteoporosis, infections, cancer, or trauma accidents, could find themselves with new bones up to seven times stronger than an original bone. Cleft palates, currently treated with a series of surgeries spanning over years, could be healed in infancy.

In addition, Meretzki estimates that the procedure, if and when it is adopted by hospitals, will cost less than the current bone regrowth treatment, which can cost up to $90,000.

The new developments are being spearheaded by Meretzki, along with Prof. Ephraim Tzur, scientific adviser of Bonus Biogroup, and Prof. Nimrod Rozen, head of the orthopedic ward of Haemek Hospital.

The second trial will consist of over 60 operations, with two groups of patients, cranial and orthopedic, and will be followed by another trial with a larger group of participants. According to Meretzki, the bone regenerating treatment is expected to finish its trials, gain FDA approval and hit the market in three to four years.

In the next stage of development, the team hopes to focus on regenerating fat and cartilage. The goal is to create “spare parts” for human beings, to be able to heal knees, hips, shoulders and elbows. Regenerating fat would allow them to replace silicon breast implants with actual fat from the patient’s body.

By Sivan Geffen | The Times of Israel

Image Credit: Bonus BioGroup

READ MORE

About Peter Coffaro 418 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the medical device industry. As a District Sales Manager for Stryker Orthopaedics, Peter was responsible for managing and directing a regional sales force to achieve sales and profit goals within the Rocky Mountain region. Previously, he was the Director of Sales & Marketing for Amp Orthopedics. In this role, Peter was responsible for planning, developing, and leading all sales and marketing initiatives. Peter is a former orthopedic distributor in the Pacific Northwest. He has also worked with DePuy Orthopaedics as well as Zimmer, and held positions in sales, sales training, and sales management. Peter has an extensive background in organizational development, business development, sales management, negotiating and P&L management. Peter holds a B.S. degree in Biology from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.